Plasma Type I IFN Protein Concentrations in Human Tuberculosis.


Journal

Frontiers in cellular and infection microbiology
ISSN: 2235-2988
Titre abrégé: Front Cell Infect Microbiol
Pays: Switzerland
ID NLM: 101585359

Informations de publication

Date de publication:
2019
Historique:
received: 13 05 2019
accepted: 31 07 2019
entrez: 12 9 2019
pubmed: 12 9 2019
medline: 14 7 2020
Statut: epublish

Résumé

Tuberculosis (TB) remains one of the leading causes of mortality worldwide, and a lack of understanding of basic disease pathogenesis is hampering development of new vaccines and treatments. Multiple studies have previously established a role for type I interferon (IFN) in TB disease. Type I IFNs are critical immune mediators for host responses to viral infection, yet their specific influence in bacterial infection remains unclear. As IFN-stimulated genes (ISGs) can have both stimulatory and inhibitory effects on immune function, clarifying the role of type I interferon in TB remains an important question. The quantification of interferon proteins in the circulation of patients has been restricted until the recent development of digital ELISA. To test the hypothesis that patients with active TB disease have elevated circulating type I IFN we quantified plasma IFNα and β proteins with Simoa digital ELISA in patients with active disease and asymptomatic

Identifiants

pubmed: 31508378
doi: 10.3389/fcimb.2019.00296
pmc: PMC6713931
doi:

Substances chimiques

Blood Proteins 0
Immunologic Factors 0
Interferon Type I 0
Interferon-alpha 0
Interferon-beta 77238-31-4

Banques de données

figshare
['10.6084/m9.figshare.8799131']

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

296

Références

Nat Rev Microbiol. 2010 Mar;8(3):242; author reply 242
pubmed: 20084059
Nature. 2010 Aug 19;466(7309):973-7
pubmed: 20725040
Genes Immun. 2011 Jan;12(1):15-22
pubmed: 20861863
Annu Rev Immunol. 2013;31:475-527
pubmed: 23516984
PLoS One. 2013 Aug 05;8(8):e70630
pubmed: 23940611
PLoS Med. 2013 Oct;10(10):e1001538
pubmed: 24167453
Nat Rev Immunol. 2015 Feb;15(2):87-103
pubmed: 25614319
Lancet. 2016 Jun 4;387(10035):2312-2322
pubmed: 27017310
Cell. 2016 Jul 28;166(3):582-595
pubmed: 27426947
J Exp Med. 2017 May 1;214(5):1547-1555
pubmed: 28420733
Tuberculosis (Edinb). 2018 Jan;108:124-126
pubmed: 29523312
J Exp Med. 2018 May 7;215(5):1273-1285
pubmed: 29666166
Nat Immunol. 2018 Jun;19(6):625-635
pubmed: 29777224
Nat Commun. 2018 Jun 19;9(1):2308
pubmed: 29921861
Biomedicine. 1979 Dec;31(9-10):267-71
pubmed: 94549

Auteurs

Alba Llibre (A)

Laboratory of Dendritic Cell Immunobiology, Department of Immunology, Institut Pasteur, Paris, France.
INSERM U1223, Institut Pasteur, Paris, France.

Nicole Bilek (N)

South African Tuberculosis Vaccine Initiative, Division of Immunology, Department of Pathology, Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town, South Africa.

Vincent Bondet (V)

Laboratory of Dendritic Cell Immunobiology, Department of Immunology, Institut Pasteur, Paris, France.
INSERM U1223, Institut Pasteur, Paris, France.

Fatoumatta Darboe (F)

South African Tuberculosis Vaccine Initiative, Division of Immunology, Department of Pathology, Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town, South Africa.

Stanley Kimbung Mbandi (SK)

South African Tuberculosis Vaccine Initiative, Division of Immunology, Department of Pathology, Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town, South Africa.

Adam Penn-Nicholson (A)

South African Tuberculosis Vaccine Initiative, Division of Immunology, Department of Pathology, Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town, South Africa.

Mark Hatherill (M)

South African Tuberculosis Vaccine Initiative, Division of Immunology, Department of Pathology, Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town, South Africa.

Flore Rozenberg (F)

Université Paris Descartes & AP-HP, Groupe Hospitalier Universitaire Paris Centre, Service de Virologie, Paris, France.

Thomas J Scriba (TJ)

South African Tuberculosis Vaccine Initiative, Division of Immunology, Department of Pathology, Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town, South Africa.

Darragh Duffy (D)

Laboratory of Dendritic Cell Immunobiology, Department of Immunology, Institut Pasteur, Paris, France.
INSERM U1223, Institut Pasteur, Paris, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH